Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

DoMore Diagnostics And Proscia Partner To Inform Personalized Treatment Decisions For Colorectal Cancer Patients

By Author Sydney Fenkel | August 30, 2023

The partnership paves the way for delivering an integrated solution that combines DoMore Diagnostics’ CE-IVDD marked Histotype Px® Colorectal* digital biomarker with Proscia’s CE-IVDR marked Concentriq® Dx** enterprise pathology platform.

*Histotype Px is CE-marked under IVDD. For Research Use only outside the EU.
**Concentriq Dx is CE-marked under IVDR.

Our website uses cookies. By using this site, you agree to its use of cookies.